Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
Authors
Keywords
Breast cancer, PAM50, HER2, intrinsic subtypes, cardiac safety, HER2-enriched, neoadjuvant
Journal
BMC Medicine
Volume 17, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-01-09
DOI
10.1186/s12916-018-1233-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I–III HER2-positive breast cancer
- (2018) Julia Foldi et al. BREAST CANCER RESEARCH AND TREATMENT
- Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer
- (2018) Andreas Schneeweiss et al. EUROPEAN JOURNAL OF CANCER
- HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
- (2017) Antonio Llombart-Cussac et al. LANCET ONCOLOGY
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy
- (2017) Debora Fumagalli et al. JAMA Oncology
- Gene expression markers of Tumor Infiltrating Leukocytes
- (2017) Patrick Danaher et al. Journal for ImmunoTherapy of Cancer
- Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial
- (2016) M. V. Dieci et al. ANNALS OF ONCOLOGY
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
- (2016) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy
- (2015) Aleix Prat et al. BMC Medicine
- P200 Neoadjuvant therapy in HER2+ breast cancer: Opti-HER Heart run-in phase safety data (SOLTI-1002)
- (2015) J. Gavilá et al. BREAST
- Clinical implications of the intrinsic molecular subtypes of breast cancer
- (2015) Aleix Prat et al. BREAST
- Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay
- (2015) A. Prat et al. CLINICAL CANCER RESEARCH
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer
- (2014) J. Baselga et al. ANNALS OF ONCOLOGY
- First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer
- (2014) L. Amiri-Kordestani et al. CLINICAL CANCER RESEARCH
- Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
- (2014) A. Prat et al. CLINICAL CANCER RESEARCH
- Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice
- (2014) Joaquín Gavilá et al. International Journal of Clinical Oncology
- Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
- (2014) Aleix Prat et al. JNCI-Journal of the National Cancer Institute
- Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients
- (2014) Patrizia Vici et al. Journal of Cancer
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
- (2013) A. Schneeweiss et al. ANNALS OF ONCOLOGY
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial
- (2013) Aman U Buzdar et al. LANCET ONCOLOGY
- Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
- (2012) Valentina Guarneri et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study
- (2011) M. Martin et al. ANNALS OF ONCOLOGY
- Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab
- (2011) D. Lenihan et al. ANNALS OF ONCOLOGY
- A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study
- (2011) Patrizia Vici et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
- (2010) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2010) Luca Gianni et al. LANCET
- Deconstructing the molecular portraits of breast cancer
- (2010) Aleix Prat et al. Molecular Oncology
- Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study
- (2009) Joseph A. Sparano et al. JOURNAL OF CLINICAL ONCOLOGY
- Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study
- (2008) J. Cortes et al. CLINICAL CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now